Summary
Cardinal Health Inc. reported a challenging fiscal year 2013, marked by a significant 6% revenue decline to $101.1 billion, largely attributed to the expiration of its pharmaceutical distribution contract with Express Scripts and ongoing brand-to-generic pharmaceutical conversions. Despite this revenue decrease, the company saw an 8% increase in gross margin to $4.9 billion, driven by strong performance in its pharmaceutical segment's generic programs. However, operating earnings were substantially impacted, falling 44% to $1.0 billion, primarily due to an $829 million non-cash goodwill impairment charge related to its Nuclear Pharmacy Services division. The company also completed a major acquisition of AssuraMed for $2.07 billion, which is expected to expand its reach in serving homecare providers and patients. A significant event impacting the upcoming fiscal year is the non-renewal of the pharmaceutical distribution contract with Walgreens, which represented approximately 20% of fiscal 2013 revenue. Management anticipates an adverse impact from this contract expiration but is implementing cost reduction measures to mitigate it. The company expects a positive net after-tax benefit to cash flow from operating activities exceeding $500 million in fiscal 2014 as a result of the expected working capital changes following the Walgreens contract expiration.
Financial Highlights
48 data points| Revenue | $101.09B |
| Cost of Revenue | $96.17B |
| Gross Profit | $4.92B |
| SG&A Expenses | $2.88B |
| Operating Income | $996.00M |
| Interest Expense | $123.00M |
| Net Income | $334.00M |
| EPS (Basic) | $0.98 |
| EPS (Diluted) | $0.97 |
| Shares Outstanding (Basic) | 341.00M |
| Shares Outstanding (Diluted) | 344.00M |
Key Highlights
- 1Revenue for fiscal year 2013 decreased by 6% to $101.1 billion, primarily due to contract expirations (Express Scripts) and brand-to-generic pharmaceutical conversions.
- 2Gross margin increased by 8% to $4.9 billion, driven by strong performance in generic pharmaceutical programs and acquisitions.
- 3Operating earnings significantly decreased by 44% to $1.0 billion due to an $829 million non-cash goodwill impairment charge in the Nuclear Pharmacy Services division.
- 4The company acquired AssuraMed for $2.07 billion, strengthening its presence in the homecare market.
- 5The key pharmaceutical distribution contract with Walgreens will not be renewed upon its expiration at the end of August 2013, impacting future revenue.
- 6Cardinal Health expects the expiration of the Walgreens contract to result in a net after-tax benefit to cash flow from operating activities exceeding $500 million in fiscal 2014 due to working capital changes.
- 7The company's effective tax rate for fiscal 2013 was significantly impacted by the non-deductible goodwill impairment charge.